August 21, 2025 a 03:43 pm
BSX: Fundamental Ratio Analysis - Boston Scientific Corporation
Boston Scientific Corporation, operating in the medical device sector, presents a mixed financial outlook with its current ratings suggesting room for improvement. Its diverse product line positions it well in the healthcare industry, yet the company's fundamentals indicate potential risks that investors should consider.
Fundamental Rating
The fundamental rating for Boston Scientific reflects a marginally below average performance in key financial metrics.
| Category | Score | Visualization |
|---|---|---|
| Discounted Cash Flow | 4 | |
| Return on Equity | 1 | |
| Return on Assets | 1 | |
| Debt to Equity | 1 | |
| Price to Earnings | 1 | |
| Price to Book | 1 |
Historical Rating
The historical ratings present a stable score over the recent period, with no significant changes observed.
| Date | Overall | DCF | ROE | ROA | Debt/Equity | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2025-08-20 | 1 | 4 | 1 | 1 | 1 | 1 | 1 |
| Previous | 0 | 4 | 1 | 1 | 1 | 1 | 1 |
Analysts' Price Targets
Analysts have provided a range of price targets, indicating confidence in the stock's potential upside.
| High | Low | Median | Consensus |
|---|---|---|---|
| 124 | 117 | 119.5 | 120 |
Analysts' Sentiment
The consensus among analysts displays a favorable view, with a strong inclination toward a 'Buy' recommendation.
| Recommendation | Count | Distribution |
|---|---|---|
| Strong Buy | 2 | |
| Buy | 37 | |
| Hold | 3 | |
| Sell | 0 | |
| Strong Sell | 0 |
Conclusion
Boston Scientific faces challenges with its current fundamental metrics; however, its robust product line and industry position provide growth opportunities. The analyst sentiment is predominantly positive, indicating optimism for future performance. Investors should monitor the company's ability to improve its financial indicators while leveraging its market position. While prospects appear promising, diligence in understanding the potential risks is recommended.